Skip to content

NOREVA BE

Active
Private limited companyfounded 201610 yrs activeKortrijksesteenweg 1126, 9051 Gent, BelgiumKBO/BCE: BE 0647.650.984
Summary

NOREVA BE has been active since 2016 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €75,384 and a net result of €42,842. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 78% of 13507 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).

Risk analysisWatch ReportCompare
NOREVA BEActiveChecked score 95/100
Risk analysis ReportCompare

Overview

Activity
Wholesale of pharmaceutical and medical goods
NACE 46460
1 site
Size
€99,431total assets 2025
Equity
€75,384
Profit
€42,842
Turnover not published (abridged schema)
Financial health
95 Excellent Checked score 2025
Bankruptcy chance 12 m
0.2%
Structure
Accounts 104 d early0 of 3 deeds read
Why 95- Size: total assets €99,431+ Liquidity: current ratio 4.13, cash €18,785+ Equity €75,384 (75.8% of total assets)+ Figures for FY 2025 (filed 16-01-2026)Show the evidence

Checked score

Score 2025
95 / 100
Excellent
Probability in this band: under 0.55%
Better than 88% of its sector peers (NACE 46, micro)
Performance against the sector, not lower risk
Every signal that weighs is under Signals.
Financial strength · tick = 2024
Strong
Solvency 100+51
equity 75.8% of total assets
Liquidity 65+44
short-term debt 24.2% · cash 18.9%
Profitability 100+43
return on assets 43.1%
Bankruptcy probability, 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%

About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.4% (26,858 companies)
Last 24 months 11-2024: 1.1%highest value 12-2024: 1.1%● 0.0% vs 11-2024highest value 01-2025: 0.6%▼ -47.6% vs 12-2024 02-2025: 0.6%● 0.0% vs 01-2025 03-2025: 0.6%● 0.0% vs 02-2025 04-2025: 0.6%● 0.0% vs 03-2025 05-2025: 0.6%● 0.0% vs 04-2025 06-2025: 0.6%▼ -0.7% vs 05-2025 07-2025: 0.6%▼ -4.7% vs 06-2025 08-2025: 0.6%● 0.0% vs 07-2025 09-2025: 0.6%● 0.0% vs 08-2025 10-2025: 0.6%▼ -1.1% vs 09-2025 11-2025: 0.6%● 0.0% vs 10-2025 12-2025: 0.6%● 0.0% vs 11-2025 01-2026: 0.7%▲ +16.1% vs 12-2025 02-2026: 0.2%▼ -71.5% vs 01-2026 03-2026: 0.2%● 0.0% vs 02-2026 04-2026: 0.2%● 0.0% vs 03-2026 05-2026: 0.2%● 0.0% vs 04-2026 06-2026: 0.2%● 0.0% vs 05-2026 07-2026: 0.2%▼ -17.3% vs 06-2026 08-2026: 0.2%● 0.0% vs 07-2026 09-2026: 0.2%● 0.0% vs 08-2026 10-2026: 0.2%▼ -1.3% vs 09-2026lowest value
  • Liquidity: current ratio 4.13, cash €18,785 lowers the probability
  • Size: total assets €99,431 raises the probability for this profile
  • Equity €75,384 (75.8% of total assets) lowers the probability
  • Figures for FY 2025 (filed 16-01-2026) lowers the probability
Credit up to €7,000 at 30 days acceptable
Liquidity ample (current ratio 4.13 against 1.31 in 2024; short-term debt: 24.2% and cash: 18.9% of total assets), and 24.2% of the assets are financed with debt.
How it is calculated

The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 46, micro). Better than this share of them on solvency 90%, liquidity 71%, profitability 95%, growth against the median 95%. That is performance, not lower risk; the band itself always comes from the probability.

Bankruptcy probability: model pd-v3.202610021621, computed on 06-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.

Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Liquidity: current ratio 4.13, cash €18,785
In the bankruptcy model this factor lowers the probability.
NBB · annual accounts
raises risk · Size: total assets €99,431
In the bankruptcy model this factor raises the probability for this profile.
NBB · annual accounts
lowers risk · Equity €75,384 (75.8% of total assets)
In the bankruptcy model this factor lowers the probability.
NBB · annual accounts
lowers risk · Figures for FY 2025 (filed 16-01-2026)
In the bankruptcy model this factor lowers the probability.
NBB · annual accounts
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025
Equity per financial year
19202122232425
2019 to 2025 · latest year €75,384
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 16-01-2026, 104 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
104 d early
2024
149 d early
2023
106 d early
2022
117 d early
2021
52 d early
2020
37 d early
2019
52 d early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 88 days before the deadline; the sector median for financial year 2024 is 3 days before the deadline, and 39% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 30-09-2026 and is due by 30-04-2027. Nothing is late today. Usually files around 15 January (4 of the last 5 filed years within 44 days of that day).
Companies Code · seven months
Position in the running window
30-09-2026 close06-10-2026 today30-04-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage
  1. Annual accounts filedfiscal year 2025 · micro…
  2. Liquidity triplescurrent ratio 4.13
  3. Annual accounts filedfiscal year 2024 · micro…

Key points

  • Positive: Among the best 18% on net resultsector median €5,574 · 13,515 companies €42,842 View
  • Positive: Always filed on timeaccounts within the deadline every year 8 years View
  • Positive: 7 profitable years in a rowprofit 2025: €42,842 7 years View

By topic

Financials

Fiscal year
2025
Total assets
€99,431
Profit
€42,842
Solvency
75.8%
Total assets▼ 27.7%
Net result
20192025
Go to Financials

Timeline

Events
12
Since
2017
Next accounts
by 30-04-2027
  1. 16-01-2026Annual accounts filed
  2. 30-09-2025Liquidity triples
  3. 02-12-2024Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Wholesale of pharmaceutical and medical goodsNACE 46460
Founded
29-01-2016
Year ends
30-09
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure